Mirum Pharmaceuticals, Inc.

Listed Company

MIRMCIK 0001759425NasdaqLarge AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$521.31M

Net Income

$-23.36M

Total Assets

$842.81M

Equity

$314.69M

Shares Out

60.98M

Op. Cash Flow

$55.83M

MIRM$118.80+125.34% · past yearDBEQ Basic

Daily closing prices

Business

Mirum Pharmaceuticals is a biopharmaceutical company that develops and commercializes medicines for rare diseases. The company's approved products include Livmarli (maralixibat) for cholestatic pruritus, Cholbam (cholic acid) for bile acid synthesis disorders, and Ctexli (chenodiol) for cerebrotendinous xanthomatosis. Clinical-stage candidates include volixibat for primary sclerosing cholangitis and primary biliary cholangitis, brelovitug for hepatitis D virus infection, and MRM-3379 for fragile X syndrome. Mirum commercializes approved medicines through direct specialty sales teams in the United States, Canada, and Europe, and via licensing agreements in additional territories.

Summary from 10-K filed 2026-02-25

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	521	337	186	77	19
Cost of sales	100	82	47	12	—
Research and development	186	141	103	107	131
Selling, general and administrative	257	202	146	89	59
Total operating expenses	543	424	296	208	193
Loss from operations	−22	−88	−109	−131	−173
Interest income	13	14	14	4	366,000
Interest expense	−14	−14	−15	−16	—
Loss from termination of revenue interest purchase agreement	0	0	−49	0	0
Other income (expense), net	2	1	−3	365,000	−582,000
Loss before provision for income taxes	−21	−87	−162	−142	−84
Provision for income taxes	2	1	991,000	−6	37,000
Net loss	−23	−88	−163	−136	−84
Net loss per share, basic (in dollars per share)	−0.47	−1.85	−4	−4.01	−2.77
Net loss per share, diluted (in dollars per share)	−0.47	−1.85	−4	−4.02	−2.77
Weighted-average shares of common stock outstanding, basic (in shares)	50	48	41	34	30
Weighted-average shares of common stock outstanding, diluted (in shares)	50	48	41	34	30

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2022 2022-06-30
Cash and cash equivalents	297	223	286	28	—
Short-term investments	87	58	0	124	—
Accounts receivable	123	78	68	24	—
Inventory	25	22	22	6	—
Prepaid expenses and other current assets	18	12	11	9	—
Total current assets	550	393	388	190	—
Restricted cash	1	425,000	0	—	—
Long-term investments	8	13	0	0	—
Property and equipment, net	2	1	706,000	914,000	—
Operating lease right-of-use assets	9	9	1	1	300,000
Intangible assets, net	261	250	253	59	—
Other assets	12	5	4	1	—
Total assets	843	671	647	353	—
Accounts payable	10	15	7	9	—
Accrued expenses and other current liabilities	196	112	—	—	—
Total current liabilities	206	127	87	65	—
Operating lease liabilities, noncurrent	8	8	617,000	1	—
Convertible notes payable, net, noncurrent	310	308	306	0	—
Other liabilities	5	3	4	5	—
Total liabilities	528	445	398	211	—
Commitments and contingencies	—	—	—	—	—
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, and no shares issued and outstanding as of December 31, 2025 and 2024	0	0	0	0	—
Common stock, $0.0001 par value; 200,000,000 shares authorized; 51,896,391 and 48,338,096 shares issued and outstanding as of December 31, 2025 and 2024, respectively	5,000	5,000	5,000	4,000	—
Additional paid-in capital	982	870	803	535	—
Accumulated deficit	−668	−644	−556	−393	—
Accumulated other comprehensive income (loss)	351,000	−373,000	2	−217,000	—
Total stockholders equity	315	226	249	142	—
Total liabilities and stockholders equity	843	671	647	353	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−23	−88	−163	−136	−84
Stock-based compensation	71	48	35	27	23
Depreciation and amortization	24	24	11	3	595,000
Inventory reserves and firm commitment losses	3	3	9	0	0
Amortization of debt discount and offering costs	2	2	1	0	0
Non-cash interest expense related to the revenue interest liability	0	0	5	16	18
Unrealized foreign exchange (gain) loss	−2	−1	2	0	0
Non-cash lease expense	2	1	620,000	443,000	380,000
Other	−1	−795,000	−1	−4	—
Accounts receivable	−48	−11	−44	−21	0
Prepaid and other current assets	−6	−849,000	−4	−4	−4
Inventory	−8	−3	−974,000	−3	−495,000
Other assets	−6	−1	−511,000	−127,000	−519,000
Accounts payable, accrued expenses and other liabilities	50	40	31	8	23
Operating lease liabilities	−2	−782,000	−940,000	−711,000	−649,000
Net cash provided by (used in) operating activities	56	10	−71	−120	−133
Purchase of investments	−97	−89	−27	−132	−198
Proceeds from maturities of investments	74	20	153	140	156
Purchase of property and equipment	−954,000	−993,000	−109,000	−278,000	−24,000
Cash paid for acquisition	0	0	−213	0	0
Payments made for additions to intangible assets	0	−20	−20	0	−19
Net cash used in investing activities	−24	−90	−107	8	49
Proceeds from issuance of common stock in private placement, net of issuance costs	0	0	202	0	0
Proceeds from issuance of common stock in at-the-market offerings, net of issuance costs	0	0	14	21	0
Proceeds from issuance of convertible notes, net	0	0	305	0	0
Proceeds from issuance of common stock pursuant to equity plans	40	18	10	7	2
Payments of deferred offering costs	0	0	−281,000	0	0
Payments on revenue interest liability	0	0	−196	−6	−121,000
Net cash provided by financing activities	40	18	337	109	73
Effect of exchange rate on cash, cash equivalents and restricted cash	3	−1	−133,000	12,000	−1,000
Net increase (decrease) in cash, cash equivalents and restricted cash	75	−63	158	−3	−11
Operating cash flows paid for operating lease	3	1	1	911,000	864,000
Cash paid for interest	13	13	7	0	0
Cash paid for income taxes	2	1	125,000	0	—
Accrued milestone payments classified as intangible assets, net	35	0	0	15	0
Right-of-use assets obtained in exchange for lease liabilities	2	10	473,000	285,000	0
Decrease in ROU assets and lease liabilities due to lease modification	649,000	723,000	0	0	—
Stock-based compensation capitalized to inventory	688,000	1	822,000	441,000	71,000
Conversion of convertible notes, net into shares of common stock	24,000	0	0	—	—
Issuance of common stock in connection with settlement of Contingent Milestone and Indemnification Holdback liabilities	0	0	5	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Mirum Pharmaceuticals, Inc.'s CIK number?

Mirum Pharmaceuticals, Inc.'s SEC CIK number is 0001759425 (1759425). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Mirum Pharmaceuticals, Inc.'s SEC filings?

All of Mirum Pharmaceuticals, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Mirum Pharmaceuticals, Inc. last report earnings?

Mirum Pharmaceuticals, Inc. (MIRM) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001759425-26-000036). This is Mirum Pharmaceuticals, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Mirum Pharmaceuticals, Inc.'s most recent earnings 8-K?

Mirum Pharmaceuticals, Inc.'s latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001759425-26-000036. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Mirum Pharmaceuticals, Inc.'s latest earnings 8-K →
Look up any company's CIK number →